Visit for the latest Coronavirus Disease (COVID-19) updates.
Read the 30 Days to Slow the Spread Guidance - PDF (versión en Español - PDF).

You are here

Evidence-Based Resource Summary

Strength of Evidence: 
4 out of 4
4 out of 4
Year Published: 

Fixed-Dose Combinations of Drugs versus Single-Drug Formulations for Treating Pulmonary Tuberculosis

Description of Resource: 
Tuberculosis (TB) is an important health problem, especially in developing countries. The treatment for pulmonary TB in new patients includes 4 oral medicines taken for 6 months, sometimes as fixed-dose combinations (FDCs) that are combined in 1 tablet, or taken separately as single-drug formulations. This systematic review assessed the efficacy, safety, and acceptability of FDCs compared with single-drug formulations for treating people with newly diagnosed pulmonary TB. It identified 13 randomized controlled trials that enrolled 5,824 people and found that fixed-dose combinations have similar efficacy to single-drug formulations for treating people with newly diagnosed pulmonary TB.

Evidence-Based Resource Details

help Learn more about EBR criteria
Developed By: 
Cochrane Review
Developer Type: 
Non-Federal Government
Healthy People 2020 Topic Area(s): 
Global Health
Healthy People 2020 Objectives: 
Resource Type: 
Systematic Review
Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, Roqué i Figuls M, Parker LA, Caylà J, Bonfill Cosp X. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database Syst Rev [Internet]. 2016 [cited 2017 12 5];(5):Article CD009913. doi: 10.1002/14651858.CD009913.pub2. Available from: